Meijumet SR is a pharmaceutical medication primarily used in the management and treatment of type 2 diabetes mellitus. It is a sustained-release (SR) formulation, designed to gradually release its active ingredients over time, ensuring a more consistent therapeutic effect and potentially reducing side effects compared to immediate-release versions. Meijumet SR typically combines two active components: Metformin, which decreases hepatic glucose production and improves insulin sensitivity, and another antidiabetic agent that works by increasing insulin secretion from the pancreas. This combination approach helps in effectively controlling blood sugar levels in patients with type 2 diabetes, thereby reducing the risk of diabetes-related complications when used alongside diet and exercise. It is important for patients to follow their healthcare provider's instructions regarding the use of Meijumet SR to optimize treatment outcomes and minimize adverse effects.